May 3, 2017 02:00 AM EDT

AstraZeneca commits $57.5M to seed Anticalin R&D pact with Pieris, a biotech on a roll

John Carroll

Editor & Founder

Boston-based Pieris Pharmaceuticals has rolled out its second big-money collaboration in the last four months, this time reeling in Big Pharma player AstraZeneca, which wants …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca commits $57.5M to seed Anticalin R&D pact with Pieris, a biotech on a roll

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Vertex makes money from sickle cell therapy Casgevy

Sana narrows focus again to zero in on diabetes and autoimmune disease

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

As­traZeneca com­mits $57.5M to seed An­ti­calin R&D pact with Pieris, a biotech on a roll

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

AstraZeneca commits $57.5M to seed Anticalin R&D pact with Pieris, a biotech on a roll